Effects of levosimendan on hemodynamics, local cerebral blood flow, neuronal injury, and neuroinflammation after asphyctic cardiac arrest in rats

Critical Care Medicine

Volumn 42, Issue 6, 2014, Pages

  Kelm, Robert F ^a   Wagenführer, Jürgen ^a   Bauer, Henrike ^a   Schmidtmann, Irene ^a   Engelhard, Kristin ^a   Noppens, Rüdiger R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cardiac output; cardiopulmonary resuscitation; cerebral blood flow; cerebral ischemia; inflammation; levosimendan

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVOSIMENDAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CONTROLLED STUDY; DRUG EFFECT; HEART ARREST; HEART INDEX; HEMODYNAMICS; HIPPOCAMPUS; MALE; MEAN ARTERIAL PRESSURE; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REPERFUSION; RESUSCITATION; TYMPANIC TEMPERATURE;

ANALYSIS OF VARIANCE; ANIMALS; CARDIOPULMONARY RESUSCITATION; CARDIOTONIC AGENTS; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEART ARREST; HEMODYNAMICS; HIPPOCAMPUS; HYDRAZONES; INTERLEUKIN-6; MALE; NEURONS; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84901488573     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000308     Document Type: Article

References (52)

1. McNally B, Robb R, Mehta M, et al; Centers for Disease Control and Prevention: Out-of-hospital cardiac arrest surveillance-Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005-December 31, 2010. MMWR Surveill Summ 2011; 60:1-19
2. Berdowski J, Berg RA, Tijssen JG, et al: Global incidences of out-of-hospital cardiac arrest and survi val rates: Systematic review of 67 prospective studies. Resuscitation 2010; 81:1479-1487
3. Neumar RW, Otto CW, Link MS, et al: Part 8: Adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729-S767
4. Olasveengen TM, Sunde K, Brunborg C, et al: Intravenous drug administration during out-of-hospital cardiac arrest: A randomized trial. JAMA 2009; 302:2222-2229
5. Negovsky VA: The second step in resuscitation-The treatment of the ?post-resuscitation disease?. Resuscitation 1972; 1:1-7
6. Deantonio HJ, Kaul S, Lerman BB: Reversible myocardial depression in survivors of cardiac arrest. Pacing Clin Electrophysiol 1990; 13:982-985
7. McCaul CL, McNamara P, Engelberts D, et al: The effect of global hypoxia on myocardial function after successful cardiopulmonary resusci tation in a laboratory model. Resuscitation 2006; 68:267-275
8. Xu T, Tang W, Ristagno G, et al: Postresuscitation myocardial diastolic dysfunction following prolonged ventricular fibrillation an d cardiopulmonary resuscitation. Crit Care Med 2008; 36:188-192
9. Fischer M, Hossmann KA: No-reflow after cardiac arrest. Intensive Care Med 1995; 21:132-141
10. Bött iger BW, Krumnikl JJ, Gass P, et al: The cerebral ?no-reflow? phenomenon after cardiac arrest in rats-Influence of low-flow reperfusion. Resuscitation 1997; 34:79-87
11. Adrie C, Adib-Conquy M, Laurent I, et al: Successful cardiopulmonary resuscitation after cardiac arrest as a " sepsis-like" syndrome. Circulation 2002; 106:562-568
12. Liachenko S, Tang P, Hamilton RL, et al: Regional dependence of cerebral reperfusion after circulatory arrest in rats. J Cereb Blood Flow Metab 2001; 21:1320-1329
13. Buunk G, van der Hoeven JG, Frölich M, et al: Cerebral vasoconst riction in comatose patients resuscitated from a cardiac arrest Intensive Care Med 1996; 22:1191-1196
14. Hauck EF, Apostel S, Hoffmann JF, et al: Capillary flow and diameter changes during reperfusi on after global cerebral ischemia studied by intravital video microscopy. J Cereb Blood Flow Metab 2004; 24:383-391
15. Kempski O, Behmanesh S: Endothelial cell swelling and brain perfusion. J Trauma 1997; 42:S38-S40
16. Hossmann KA: Ischemia-mediated neuronal injury. Resuscitation 1993; 26:225-235
17. Nolan JP, Neumar RW, Adrie C, et al: Post-car diac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation 2008; 79:350-379
18. Pagel PS, Harkin CP, Hettrick DA, et al: Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anes thesiology 1994; 81:974-987
19. Delaney A, Bradford C, McCaffrey J, et al: Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. Int J Car diol 2010; 138:281-289
20. Koudouna E, Xanthos T, Bassiakou E, et al: Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest. Acta Anaesthe siol Scand 2007; 51:1123-1129
21. Huang L, Weil MH, Tang W, et al: Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med 2005; 33:487-491
22. Huang L, Weil MH, Sun S, et al: Levosimendan improves postresuscitation outcomes in a rat model of CPR. J Lab Clin Med 2005; 146:256-261
23. Y okoshiki H, Katsube Y, Sunagawa M, et al: Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997; 333:249-259
24. Y ildiz O: Vasodilating mechanisms of levosimendan: Involvement of K+ channels. J Pharmacol Sci 2007; 104:1-5
25. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al: Coronary vasorelaxant effect o f levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998; 31:741-749
26. Fries M,Ince C,Rossaint R,et al, Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock, Crit Care Med,2008,36, 1886-1891.
27. Parissis JT, Adamopoulos S, Antoniades C, et al: Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93:1309-1312
28. Adamopoulos S, Parissis JT, Iliodromitis EK, et al: Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart fail ure. Am J Cardiol 2006; 98:102-106
29. Kelm RF, Wagenfü hrer J, Schmidtmann I, et al: Transpulmonary cardiac output measurement in a rat model of cardiac arrest and CPR: Impact of vascular access. Resuscitation 2010; 81:248-254
30. Hickey RW, Ferimer H, Alexander HL, et al: Delayed, spontaneous hypothermia reduces neuronal damage after asphyxial cardiac arrest in rats. Crit Care Med 2000; 28:3511-3516
31. Hendrickx HH, Safar P, Miller A: Delayed recovery of behavior after anesthesia in rats. Resuscitation 1984; 12:213-221
32. Katz L, Ebmeyer U, Safar P, et al: Outcome model of asphyxial cardiac arrest in rats. J Cereb Blood Flow Metab 1995; 15:1032-1039
33. Noppens RR, Kelm RF, Lindemann R, et al: Effects of a singledose hypertonic saline hydroxyethyl starch on cerebral blood flow, long-term outcome, neurogenesis, and neuronal survival after cardiac arrest and cardiopulmonary resuscitation in rats. Crit Care Med 2012; 40:2149-2156
34. Schmued LC, Hopkins KJ: Fluoro-Jade B: A high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000; 874:123-130
35. Sc hmued LC, Albertson C, Slikker W Jr: Fluoro-Jade: A novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 1997; 751:37-46
36. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Compact Third Edition. San Diego, Academic Press, 1997
37. Thal SC, Wyschkon S, Pieter D, et al: Selection of endogenous control genes for normalizat ion of gene expression analysis after experimental brain trauma in mice. J Neurotrauma 2008; 25:785-794
38. Langnaese K, John R, Schweizer H, et al: Selection of reference genes for quantitative real-time PCR in a rat asphyxial cardiac arrest model. BMC Mol Biol 2008; 9:53
39. Papp Z, É des I, Fruhwald S, et al: Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012; 159:82-87
40. Armstead WM: Role of ATP-sensitive K+ channels in cGMP-mediated pial artery vasodilation. Am J Physiol 1996; 270:H423-H426
41. Schilling L, Parsons AA, Wahl M: Effects of potassium channel activators on isolated cerebral arteries of large and small diameter in the cat. J Neurosurg 1995; 83:123-128
42. Janigro D, West GA, Gordon EL, et al: ATP-sensitive K+ channels in rat aorta and brain microvascular endothelial cells. Am J Physiol 1993; 265:C812-C821
43. Kågströ m E, Smith ML, Siesjö BK: Local cerebral blood flow in the recovery period following complete cerebral ischemia in the rat. J Cereb Blood Flow Metab 1983; 3:170-182
44. Dirnagl U, Kaplan B, Jacewicz M, e t al: Continuous measurement of cerebral cortical blood flow by laser-Doppler flowmetry in a rat stroke model. J Cereb Blood Flow Metab 1989; 9:589-596
45. Sundgreen C, Larsen FS, Herzog TM, et al: Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest. Stroke 2001; 32:128-132
46. Sterz F, Leonov Y, Safar P, et al: Hypertension with or without hemodilution after cardiac arrest in dogs. Stroke 1990; 21:1178-1184
47. Roehl AB,Hein M,Loetscher PD,et al. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury, BMC Neurol2010,10,97
48. Antila S, Huuskonen H, Nevalainen T, et al: Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 1999; 9:85-91
49. Roehl AB, Zoremba N, Kipp M, et al: The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia. BMC Neurol 2012; 12:81
50. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al: The Ca2+-sensitizer levosimendan improves oxidative damage, BN P and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005; 7:882-887
51. Hasslacher J, Bijuklic K, Bertocchi C, et al: Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study. Crit Care 2011; 15:R166
52. Ji M, Li R, Li GM, et al: Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock. Inflammation 2012; 35:871-880